Regular readers will know that our Kit Yamoyo anti-diarrhoea kit has design features that respond to the needs of the mothers we talked to as part of the design process. A technique we now know is called ‘Human Centred Design’.
Two key features of Kit Yamoyo help mothers mix the ORS correctly:
- The inclusion of ORS sachets that make up 200 ml (the standard ones make up 1 litre and were designed for institutional use, not for use in the home)
- The fact that the Kit Yamoyo container also acts as a measuring device for the correct amount of water and is also a mixing device and cup
Early indications show that mothers using a Kit Yamoyo get the mixing right more than 90% of the time whereas those that are given 1 litre sachets get it wrong about half of the time.
This is an example of how product design can improve adherence to the correct use of the ORS.
But we remain with a challenge that we’d like your help with and here it is.
To get the full effect of the Zinc tablets included in the kit, children should be given them for 10 days. Half a tablet a day for children under 6 months and a whole tablet for children over 6 months. However, early results show that only around 25% of children are given the tablets for a full 10 days. When the diarrhoea stops, mothers tend to stop giving the Zinc. Although this does no harm, children will not get the full benefit of the kit if they do not complete the Zinc course. Zinc strengthens the immune system and so helps protect against future bouts of diarrhoea.
Is there a design adaptation we could make to increase adherence to Zinc in the same way as we have increased the correct use of ORS?
For your information, here is the Zinc panel of the instruction leaflet in English. The leaflet in the commercial kits is in 3 languages and can be viewed and downloaded here.
But note that only around half of our users consulted this leaflet!
Over to you . . .
A note on the data in this post
Cited data are interim results from the midline evaluation and do not reflect the final report.
Final calculations may vary.
Final results of the ColaLife trial will be published in due course by Ramchandani R, et al.